image credit: Freepik

Triveni emerges from biotech merger with $92M for immune disease drugs

October 26, 2023

Triveni sees an opportunity to advance eczema treatment in a similar way to how psoriasis medicines have improved over the past decade, said Vishal Patel, the company’s CEO.

In psoriasis, pills like Bristol Myers Squibb’s Sotyktu have joined mainstay biologics such as Amgen’s Enbrel and AbbVie’s Humira, spurring the entry of new competitors attempting to develop safer and more effective medicines.

Read More on Biopharma Dive